← Leaderboards
Jacob Brenner
University Of Pennsylvania
$6,438,045
Attributed
$9,465,971
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,465,971 · 9
By mechanism
R01$6,785,298 · 3
R41$1,372,763 · 3
K08$746,064 · 1
R21$446,875 · 1
F32$114,971 · 1
Top collaborators
- Vladimir R Muzykantov4 shared
- Wenchao Song4 shared
- Hamideh Parhiz3 shared
- Vera P Krymskaya1 shared
- Dirk Pleimes1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Vera P Krymskaya$16,207,847
- Michael Francis Beers$18,247,357
- Wenchao Song$30,516,555
- Ronald G Collman$30,299,814
- Abraham Na Shaked$18,454,681
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsDrug Delivery SystemsMouse ModelAntibodiesBlood CapillariesAcuteDesignLungEndotheliumTechnologyLiposomesDrug CarriersPreventSide EffectEndothelial CellsUptakeFunctional DisorderBindingIn VivoNovel TherapeuticsInflammatoryNanocarrierTherapeutic EffectOrgan
Grant awards (27)
Controlling complement to unleash nanomedicine for acute critical illnesses$695,095
R01 · FY2025 · HL · contact PI
mRNA-LNPs for ARDS$683,436
R01 · FY2025 · HL
Next-generation nanomedicine for acute ischemic stroke$351,461
R41 · FY2025 · NS · contact PI
mRNA-LNPs for ARDS$694,692
R01 · FY2024 · HL
Controlling complement to unleash nanomedicine for acute critical illnesses$681,194
R01 · FY2024 · HL · contact PI
Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillaries$406,250
R01 · FY2024 · HL · contact PI
The DOVE Device to Prevent Opioid Overdose Deaths: An Armband That Senses Overdose and Automatically Injects Naloxone$55,000
R41 · FY2024 · DA · contact PI
The DOVE Device to Prevent Opioid Overdose Deaths: An Armband That Senses Overdose and Automatically Injects Naloxone$44,902
R41 · FY2024 · DA · contact PI
Controlling complement to unleash nanomedicine for acute critical illnesses$695,095
R01 · FY2023 · HL · contact PI
mRNA-LNPs for ARDS$679,571
R01 · FY2023 · HL
Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillaries$406,250
R01 · FY2023 · HL · contact PI
The DOVE Device to Prevent Opioid Overdose Deaths: An Armband That Senses Overdose and Automatically Injects Naloxone$319,930
R41 · FY2023 · DA · contact PI
miRNA-Nanotechnology as a novel regenerative therapy for lymphangioleiomyomatosis$301,016
R41 · FY2023 · HG
Next-generation nanomedicine for acute ischemic stroke$300,454
R41 · FY2023 · NS · contact PI
Controlling complement to unleash nanomedicine for acute critical illnesses$626,215
R01 · FY2022 · HL · contact PI
Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillaries$406,250
R01 · FY2022 · HL · contact PI
RBC-mediated mopping of cytokines for the treatment of pneumonia$243,750
R21 · FY2022 · AI · contact PI
Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillaries$406,250
R01 · FY2021 · HL · contact PI
RBC-mediated mopping of cytokines for the treatment of pneumonia$203,125
R21 · FY2021 · AI · contact PI
Nanonscale drug carriers for the treatment of acute respiratory distress syndrome$119,988
K08 · FY2021 · HL · contact PI
Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillaries$405,000
R01 · FY2020 · HL · contact PI
Nanonscale drug carriers for the treatment of acute respiratory distress syndrome$119,988
K08 · FY2020 · HL · contact PI
Nanonscale drug carriers for the treatment of acute respiratory distress syndrome$168,696
K08 · FY2019 · HL · contact PI
Nanonscale drug carriers for the treatment of acute respiratory distress syndrome$168,696
K08 · FY2018 · HL · contact PI
Nanonscale drug carriers for the treatment of acute respiratory distress syndrome$168,696
K08 · FY2017 · HL · contact PI
Targeted Drug Delivery For Acute Respiratory Distress Syndrome$55,005
F32 · FY2016 · HL · contact PI
Targeted Drug Delivery For Acute Respiratory Distress Syndrome$59,966
F32 · FY2015 · HL · contact PI